Azerion Launches Hawk DSP in US, Hawk Announced as Partner for Scope3 Agentic Media Platform
Azerion's cost-effective DSP comes to the US, makes curated audiences available to Scope3's customers.
'Hawk's cutting-edge technology and innovative solutions play an important role in the ongoing success of OMG's Outcomes business.' — Amit Maniar, Head of Solutions, Global Investments at Omnicom Media Group
NEW YORK, NY, UNITED STATES, March 14, 2025 / EINPresswire.com / -- Azerion, the international, publicly listed adtech full-stack platform and leading curation house, has launched Hawk, a demand-side platform (DSP), in the US. Hawk is a cost-effective DSP that allows advertisers to access audiences that have been curated on the sell side at the most competitive rates available, delivering more for each dollar.
Hawk leverages Azerion's background as a leading sell-side curation provider to offer curated inventory based on publisher signals at no added cost. It is the only DSP to offer cost-effective curation, omnichannel capabilities, global reach and geo-based targeting.
'Hawk fundamentally changes the economics of programmatic for the better,' said Matthew Newcomb, regional director of Azerion in the US, UK, and APAC. 'By providing curation at a fifth of the cost of alternative DSPs, we give advertisers access to the most relevant and performant audiences and inventory while putting more of each dollar toward working media.'
Scope3, the platform powering safe, sustainable growth in media and advertising, launched its Agentic Media Platform on March 13. It allows publishers, ad tech platforms, curators and agencies to create agentic media products that leverage AI agents and custom algorithms to deliver more effective media buying for brands.
Hawk is a launch partner of the Agentic Media Platform, as its curation abilities and competitive rates align with Scope3's vision for a more transparent and efficient advertising ecosystem.
'We partnered with Azerion because we share the vision of a collaborative, efficient supply chain with easy-to-use, affordable tools to help buyers drive sustainable growth,' said Brian O'Kelley, Co-Founder and CEO of Scope3. 'The Hawk DSP, built on top of the Scope3 'greenstream', is a perfect way for advertisers to drive omnichannel performance without worrying about high costs.'
'Hawk's cutting-edge technology and innovative solutions play an important role in the ongoing success of OMG's Outcomes business,' said Amit Maniar, Head of Solutions, Global Investments at Omnicom Media Group. 'We greatly appreciate their forward-thinking partnership and the added value they bring through strategic collaborations and market expansion.'
With its roots in sell-side curation, Azerion is poised to help advertisers get the most relevant audiences possible on every channel with maximum efficiency. By partnering with Scope3, it will help advertisers drive sustainable growth and efficient performance at scale.
About Azerion
Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe's largest digital advertising and entertainment media platforms. Azerion brings global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technology, in a safe, engaging, and high quality environment, utilising our strategic portfolio of owned and operated content with entertainment and other digital publishing partners.
Having its roots in Europe and with its headquarters in Amsterdam, Azerion has commercial teams based in over 21 cities around the world to closely support our clients and partners to find and execute creative ways to make a real impact through advertising.
Joe Zappa
X
LinkedIn
Instagram
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative
Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative June 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company's headquarters located at Sundesk Sophia Antipolis, rue Evariste Galois, Emerald Square, Bâtiment C – 06410 agenda and the text of the draft resolutions proposed to the Ordinary and Extraordinary Shareholders' Meeting are included in the notice of meeting published in the Bulletin des Annonces Légales Obligatoires (Official Bulletin of Mandatory Legal Announcements) No. 61 dated May 21, 2025 (No. 2502198) and No. 64 dated May 28, 2025 ( No. 2501651).Appointment of an A Representative to Represent Defaulting ShareholdersIn light of the significant difficulties in reaching the required quorum, the President of the Antibes Commercial Court, has appointed by order on May 6, 2025, SCP EZAVIN-THOMAS, represented in the person of Maître Nathalie Thomas, domiciled 1, Alexandre Mari – 06000 Nice, as ad hoc representative to represent defaulting shareholders at the Ordinary and Extraordinary Shareholder's Meeting convened for June 27, 2025 on first ad hoc representative will thus represent all the shares with voting rights held by shareholders who have not participated or are not represented at this General Meeting. The participation of the ad hoc representative will thus bring the quorum to 100% of shares with voting order to ensure the neutrality of the ad hoc representative's role, the voting rights attached to the shares of the defaulting shareholders will be exercised as follows: for ordinary resolutions, whether proposed, approved or not approved by the Board of Directors: half the votes in favor and half against; for extraordinary resolutions whether proposed or approved by the Board of Directors: two-thirds in favor and one-third against; for extraordinary resolutions not approved by the Board of Directors: one-third in favor and two-thirds against; Documentation and Participation in the General MeetingThe documents relating to the General Meeting, including the text of the draft resolutions and the proxy form, are made available to shareholders at the Company's headquarters and on its website ( may vote by proxy, by internet or by attending the Ordinary and Extraordinary Shareholder Meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company's website. Shareholders may also contact the Company's Investor Relations team at ag2025nicox@ for any questions regarding the voting process. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Nicox_CP_Annonce_AGOA_Mandataire_ad_hoc_FINALSign in to access your portfolio
Yahoo
a day ago
- Yahoo
Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative
Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative June 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company's headquarters located at Sundesk Sophia Antipolis, rue Evariste Galois, Emerald Square, Bâtiment C – 06410 agenda and the text of the draft resolutions proposed to the Ordinary and Extraordinary Shareholders' Meeting are included in the notice of meeting published in the Bulletin des Annonces Légales Obligatoires (Official Bulletin of Mandatory Legal Announcements) No. 61 dated May 21, 2025 (No. 2502198) and No. 64 dated May 28, 2025 ( No. 2501651).Appointment of an A Representative to Represent Defaulting ShareholdersIn light of the significant difficulties in reaching the required quorum, the President of the Antibes Commercial Court, has appointed by order on May 6, 2025, SCP EZAVIN-THOMAS, represented in the person of Maître Nathalie Thomas, domiciled 1, Alexandre Mari – 06000 Nice, as ad hoc representative to represent defaulting shareholders at the Ordinary and Extraordinary Shareholder's Meeting convened for June 27, 2025 on first ad hoc representative will thus represent all the shares with voting rights held by shareholders who have not participated or are not represented at this General Meeting. The participation of the ad hoc representative will thus bring the quorum to 100% of shares with voting order to ensure the neutrality of the ad hoc representative's role, the voting rights attached to the shares of the defaulting shareholders will be exercised as follows: for ordinary resolutions, whether proposed, approved or not approved by the Board of Directors: half the votes in favor and half against; for extraordinary resolutions whether proposed or approved by the Board of Directors: two-thirds in favor and one-third against; for extraordinary resolutions not approved by the Board of Directors: one-third in favor and two-thirds against; Documentation and Participation in the General MeetingThe documents relating to the General Meeting, including the text of the draft resolutions and the proxy form, are made available to shareholders at the Company's headquarters and on its website ( may vote by proxy, by internet or by attending the Ordinary and Extraordinary Shareholder Meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company's website. Shareholders may also contact the Company's Investor Relations team at ag2025nicox@ for any questions regarding the voting process. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Nicox_CP_Annonce_AGOA_Mandataire_ad_hoc_FINALError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Lockheed Martin gets $9.5 million for Naval helicopter repairs
OWEGO, N.Y. (WIVT/WBGH) — Lockheed Martin in Owego has been awarded a $9.5 million contract to repair multiple U.S. Navy helicopters. Congressman Nick Langworthy (NY-23) announced the contract on Thursday, June 5, for Lockheed Martin Rotary and Mission Systems to repair H-60 Naval Hawk helicopters through 2029. Langworthy said the best in the business is on the job. 'I am thrilled that Lockheed Martin in Owego has received this substantial contract,' Congressman Langworthy said. 'Our Southern Tier workforce is the best in the nation and the opportunity to strengthen our regional economy while supporting our incredible United States Navy is a win-win.' The helicopters are manufactured by Sikorsky Aircraft, which has produced over 5,000 HAWK helicopters for a variety of mission types. Tioga County announces Concerts in the Park schedule Tariff battle continues Aaron Rodgers plans to sign with Pittsburgh Steelers: reports 'Cheers' actor George Wendt's cause of death revealed: report Musk says Trump is named in Epstein files Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
